These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27770561)

  • 81. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.
    Lawitz E; Buti M; Vierling JM; Almasio PL; Bruno S; Ruane PJ; Hassanein TI; Muellhaupt B; Pearlman B; Jancoriene L; Gao W; Huang HC; Shepherd A; Tannenbaum B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Yoshida EM
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):814-823. PubMed ID: 28802814
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
    Alric L; Bonnet D
    Expert Opin Pharmacother; 2016; 17(5):735-42. PubMed ID: 26933896
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
    Lawitz E; Reau N; Hinestrosa F; Rabinovitz M; Schiff E; Sheikh A; Younes Z; Herring R; Reddy KR; Tran T; Bennett M; Nahass R; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Pearlman B; Shiffman M; Hawkins T; Curry M; Jacobson I
    Gastroenterology; 2016 Nov; 151(5):893-901.e1. PubMed ID: 27486034
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
    Ridruejo E; Garcia-Agudo R; Mendizabal M; Aoufi-Rabih S; Dixit V; Silva M; Fabrizi F
    Nefrologia (Engl Ed); 2020; 40(1):46-52. PubMed ID: 31229261
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network.
    Flamm SL; Bacon B; Curry MP; Milligan S; Nwankwo CU; Tsai N; Younossi Z; Afdhal N
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1511-1522. PubMed ID: 29665097
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.
    Nangia G; Vierling JM; Kwo P; Brown DD; Klopfer SO; Robertson MN; Haber BA; Reddy KR
    J Viral Hepat; 2020 Nov; 27(11):1222-1233. PubMed ID: 32594612
    [TBL] [Abstract][Full Text] [Related]  

  • 87. High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway.
    Leiva RA; Bergersen BM; Finbråten AK; Sandvei PK; Simonsen Ø; Rosseland CM; Hagen K; Young L; Roberts RS; Mikkelsen Y; Singh R; Lagging M; Dalgard O
    Scand J Gastroenterol; 2023 Mar; 58(3):264-268. PubMed ID: 36063075
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence.
    Morikawa K; Nakamura A; Shimazaki T; Sakamoto N
    Drug Des Devel Ther; 2018; 12():2749-2756. PubMed ID: 30233138
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
    Papaluca T; Roberts SK; Strasser SI; Stuart KA; Farrell G; MacQuillan G; Dore GJ; Wade AJ; George J; Hazeldine S; O'Beirne J; Wigg A; Fisher L; McGarity B; Sawhney R; Sinclair M; Thomas J; Valiozis I; Weltman M; Wilson M; Woodward A; Ahlenstiel G; Haque M; Levy M; Prewett E; Sievert W; Sood S; Tse E; Valaydon Z; Bowden S; Douglas M; New K; O'Keefe J; Hellard M; Doyle J; Stoove M; Thompson AJ
    Clin Infect Dis; 2021 Nov; 73(9):e3288-e3295. PubMed ID: 32887983
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
    Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
    Suda G; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Hasebe C; Abe M; Haga H; Ueno Y; Masakane I; Abe K; Takahashi A; Ohira H; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Kawakami A; Kumagai K; Terasita K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    J Gastroenterol; 2019 Jan; 54(1):78-86. PubMed ID: 30019127
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.
    Boyd A; Miailhes P; Chas J; Valantin MA; Yazdanpanah Y; Rosenthal E; Chevaliez S; Piroth L; Rougier H; Peytavin G; Pialoux G; Girard PM; Lacombe K
    J Antimicrob Chemother; 2020 Jul; 75(7):1961-1968. PubMed ID: 32306039
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
    Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection.
    Papudesu C; Kottilil S; Bagchi S
    Hepatol Int; 2017 Mar; 11(2):152-160. PubMed ID: 27624503
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.
    Li C; Liang J; Xiang H; Chen H; Tian J
    Medicine (Baltimore); 2020 Nov; 99(48):e23384. PubMed ID: 33235113
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan.
    Tsai TC; Deng ST; Hsu CW
    J Med Virol; 2020 Feb; 92(2):219-226. PubMed ID: 31599455
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects.
    Hsieh YC; Lin CL; Hung CH; Chen CH; Tung SY; Lin CY; Hu TH; Lu SN; Chien RN; Sheen IS
    J Viral Hepat; 2020 May; 27(5):505-513. PubMed ID: 32039536
    [TBL] [Abstract][Full Text] [Related]  

  • 98. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
    Puoti M; Foster GR; Wang S; Mutimer D; Gane E; Moreno C; Chang TT; Lee SS; Marinho R; Dufour JF; Pol S; Hezode C; Gordon SC; Strasser SI; Thuluvath PJ; Zhang Z; Lovell S; Pilot-Matias T; Mensa FJ
    J Hepatol; 2018 Aug; 69(2):293-300. PubMed ID: 29551706
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [A real-world study of the efficacy and safety of sofosbuvir and velpatasvir in the treatment of HCV-infected patients in a county in northern China].
    Qiu LX; Yu HB; Lin W; Liu YR; Qiu YD; Hu ZJ; Pang XH; Zhang J; Liu YL
    Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):395-401. PubMed ID: 35545564
    [No Abstract]   [Full Text] [Related]  

  • 100. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.